While many farmers have already purchased fertiliser for this season, there will be some who haven’t been able to do that, ...
What Is Sotyktu, and Why Does It Matter? Sotyktu (deucravacitinib) is an oral selective tyrosine kinase 2 (TYK2) inhibitor used to treat autoimmune inflammatory diseases such as plaque psoriasis in ...
Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
FDA sNDAs seek approval of belzutifan plus lenvatinib for post–PD-1/PD-L1 advanced ccRCC, setting an October 4, 2026 PDUFA target action date. LITESPARK-011 randomized 747 patients to belzutifan 120 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results